British Biotech & Serono - 500 Beiträge pro Seite

[Herr Karl]

Embargoed until 17th October 2000, 6.00am


British Biotech plc ("British Biotech")
Serono & British Biotech to collaborate on inflammatory
diseases

Geneva, Switzerland, and Oxford, UK, 17th October, 2000 – Serono S.A. (SWX:
SEO and NYSE: SRA) and British Biotech plc (LSE: BBG and NASDAQ: BBIOY), today
announced that they have entered into an exclusive agreement to jointly research, develop
and commercialise metalloenzyme inhibitors (MEIs) for the treatment of serious
inflammatory diseases. In addition, British Biotech announces that BB-2827, a
collagenase inhibitor that is a potential treatment for rheumatoid arthritis, entered
clinical development in October 2000.

Serono and British Biotech will work together under the agreement to identify new
compounds for clinical development based on British Biotech`s proprietary MEI platform
technologies. Any compounds selected for clinical development will then be progressed
under the terms of an exclusive licence, development and commercialisation agreement.
Included within the scope of the agreement is an option for Serono to obtain exclusive
rights to develop and commercialise BB-2827 following completion of certain clinical
studies by British Biotech. Serono also gains rights to BB-76163, an aminopeptidase
inhibitor with potential application in multiple sclerosis.

“This partnership brings together Serono’s expertise in multiple sclerosis and other
inflammatory diseases with British Biotech’s leading position in metalloenzyme
inhibition,” commented Silvano Fumero, Senior Executive Vice President of Research &
Pharmaceutical Development at Serono. “We will continue to enhance our competitive
advantages in strategic research areas and to strengthen our early stage development
pipeline by partnering in the drug discovery process.”

Dr Elliot Goldstein, Chief Executive of British Biotech, said, “This is an important, long-
term research and development collaboration to bring new compounds to market with an
emerging world leader in inflammatory disease. The relationship with Serono continues
our strategy of collaboration with excellent partners to exploit our MEI platform,
develop new drugs in inflammatory disease and expand our portfolio of
commercialisation rights. In addition, we have met the important objective of starting
clinical trials with BB-2827.”

Under the terms of the agreement, British Biotech will receive from Serono an initial
payment of US$5 million, a series of undisclosed milestone payments, and eventual
royalties on any commercialised products. The companies will share the costs of research
equally. Costs of product development will be borne by Serono, but British Biotech has
the right to fund half of such costs and, in certain circumstances, may co-promote
products with Serono, for an improved return on sales. Depending on the achievement of
certain milestones, cash payments and research funding to British Biotech during the
term of the collaboration could total between US$30 million and US$80 million.

Ends


For more information, please contact:


British Biotech plc, Oxford, UK:
Tony Weir, Finance Director Tel: [phone]
Fax: [phone]
www.britishbiotech.com
Financial Dynamics, London, UK:
Sarah Mehanna/David Yates Tel: + 44 207 831 3113
Fax: + 44 207 242 8695
www.fd.com


Serono International S.A., Geneva,
Switzerland:
Media Relations:
Investor Relations:
Noonan/Russo
Communications:
Tel: [phone]
00
Tel: [phone]
Tel: [phone]
Fax: [phone]
85
Fax: [phone]
Fax: [phone]
Internet: www.serono.com
Reuters: SEOZ.S/SRA.N
www.noonanrusso.com

Bloomberg: SEO SW/SRA US
Tel: [phone]


Fax: [phone]

------------------------------------------------------------

http://www.serono.com/newsroom/index.htm
WKN.: 1075192 SEO.ZRH






http://www.britbio.co.uk/
WKN.: 884408 BBP.FSE





------------------------------------------------------------

Endlich wieder good news von BB!

http://www.md-verlag.de/industri/mdpharm.htm
Hier findet ihr Links zu Pharmafirmen!

Grüsse Karl

[ani]

Was ist mit euch los seid ihr alle Tod?
Heute gehts ein wenig Bergauf, hoffentlich nicht nur ein Tag

[alibert]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Herr Karl]

Hallo!

Hat es schon jemand bemerkt? - Die Homepage ist neu!

Optisch zwar konservativ, aber ansonsten gut gelungen.
http://www.britbio.co.uk/

Quelle für Charts: http://www.moneyworld.co.uk



Der Intraday-Chart


Wechselkurse: http://www.oanda.com/

Wechselkurs derzeit 0,599€ für 1 Pfund - Aktienkurs also
derzeit 0,41736€.

Grüsse Karl